Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach

Multiple Sclerosis Treatment in the COVID-19 Era: A Risk-Benefit Approach

The COVID-19 pandemic poses an ongoing global challenge, and several risk factors make people with multiple sclerosis (pwMS) particularly susceptible to running a severe disease course. Although the literature does report numerous articles on the risk factors for severe COVID-19 and vaccination resp...

Full description

Bibliographic Details
Main Authors: Paolo Immovilli, Nicola Morelli, Chiara Terracciano, Eugenia Rota, Elena Marchesi, Stefano Vollaro, Paola De Mitri, Domenica Zaino, Veronica Bazzurri, Donata Guidetti
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Neurology International
Subjects:
multiple sclerosis
COVID-19
SARS-CoV-2
anti-CD20
fingolimod
ocrelizumab
Online Access:https://www.mdpi.com/2035-8377/14/2/30

Internet

https://www.mdpi.com/2035-8377/14/2/30

Similar Items